AMRXAMRXHealthcare · Drug Manufacturers - Specialty & Generic

AMRX Stock Forecast: Amneal Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$22
+3.60% on the day

The 7 Wall Street analysts covering Amneal Pharmaceuticals, Inc. hold a median 12-month price target of $25 — +14.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 17 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$7.4B
Ticker Nerd rank
83/ 100
Median analyst target
$25
Analysts covering
7
Revenue$796.2M+9.9% y/y
Operating income$146.0M
Net income$69.6M
Free cash flow−$144.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
+14.1%
YTD
+73.7%
1Y
+89.1%
From 52W high
0.0%
From 52W low
+90.0%
$12
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amneal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
83/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Quality
93
Revisions
90
Value
90
Volatility
78
Growth
75
Accruals
24
Size
18
Issuance
11

Momentum (99): The shares have been drifting up relative to others.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AMRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26AMRXHigh $28Median $25Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $20Median $25High $28

The green dot is the last close — the median target sits +14.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
5 Nov 2026Leerink PartnersMaintainsOutperform$23 → $25
4 Nov 2026JP MorganMaintainsOverweight$24 → $25
22 Oct 2026JP MorganMaintainsOverweight—
22 Oct 2026JP MorganMaintainsOverweight$22 → $24
23 Sept 2026OppenheimerInitiatesOutperform$27
23 Sept 2026OppenheimerInitiatesOutperform—
17 Sept 2026BarclaysMaintainsOverweight$16 → $20
17 Sept 2026BarclaysMaintainsOverweight—
9 Sept 2026Leerink PartnersInitiatesOutperform—
9 Sept 2026Leerink PartnersInitiatesOutperform$23
26 Aug 2026JP MorganReinstatesOverweight$22
3 Aug 2026UBSMaintainsBuy$23 → $25
3 Aug 2026UBSMaintainsBuy—
15 July 2026UBSMaintainsBuy$19 → $23
15 July 2026UBSMaintainsBuy—
20 May 2026BarclaysMaintainsOverweight$15 → $16
20 May 2026BarclaysMaintainsOverweight—
17 Apr 2026UBSInitiatesBuy—
2 Mar 2026Truist SecuritiesMaintainsBuy—
9 Dec 2025BarclaysInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AMRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AMRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Amneal Pharmaceuticals, Inc. returned +89.1% against +12.2% for the S&P 500, dividends included.

AMRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Jan 26Apr 26Jul 26Oct 26AMRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+7.5%
Analysts raising
4
Analysts cutting
0
Fundamentals

Amneal Pharmaceuticals, Inc. (AMRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
52.8×

Cheaper than 13% of US stocks

Price / sales
2.3×

Cheaper than 46% of US stocks

Price / book
13.8×

Cheaper than 6% of US stocks

EV / EBITDA
14.6×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
10.0%

Higher than 53% of US stocks

Earnings growth (YoY)
9.9%

Higher than 49% of US stocks

Gross margin
42.0%

Higher than 52% of US stocks

Operating margin
16.7%

Higher than 76% of US stocks

Net margin
4.2%

Higher than 57% of US stocks

Returns & dividend
Return on equity
70.0%

Higher than 95% of US stocks

Return on assets
7.5%

Higher than 86% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amneal Pharmaceuticals, Inc. (AMRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amneal Pharmaceuticals, Inc. has a market value of $7.4B and an enterprise value of $10.6B.

  • Revenue in the twelve months to 30 June 2026: $3.1B. The latest quarter grew 10.0% year on year.

  • Net income over the same four quarters: $215.3M, a 6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.49.

  • Free cash flow in the twelve months to 30 June 2026: −$12.3M.

  • Shares outstanding: 319.3M.

  • Trailing P/E: 52.8×; forward P/E: 17.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Amneal Pharmaceuticals, Inc. employs 8,700 people — $358K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

AMRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMRXAmneal Pharmaceuticals, Inc.$7.4B83
KNSAKiniksa Pharmaceuticals International Plc$7.3B98
ALKSAlkermes Plc$7.5B70
LNTHLantheus Holdings, Inc.$6.6B98
SUPN.1Supernus, Inc.$6.0B89
LQDALiquidia Corp.$5.1B97
ELANElanco Animal Health, Inc.$12.9B97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amneal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMRX news & analysis

Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing

Seeking Alpha · 17 Nov 2026positive

Seeking Alpha reaffirmed its buy view on Amneal after the company reported a fourth consecutive earnings beat, with Q3 revenue up 10% and higher FY26 revenue guidance. The article cites the growing pipeline, Kashiv integration, biosimilar opportunities, positive operating cash flow, and improving operating margin.

Why it matters — AMRX watchers may note the reported results and guidance alongside pipeline and margin developments highlighted in the article.

AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised

Zacks Investment Research · 4 Nov 2026positive

Amneal Pharmaceuticals reported Q3 earnings and sales that topped estimates, with growth in Affordable Medicines and Specialty driving the results. The company also raised its FY2026 guidance.

Why it matters — AMRX watchers may note the reported business growth and higher FY2026 guidance.

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript

Seeking Alpha · 3 Nov 2026neutral

The item is a transcript of Amneal Pharmaceuticals’ Q3 2026 earnings call. The provided excerpt contains no further details about the call.

Why it matters — AMRX watchers may consult the transcript for information about the company’s quarterly earnings call, but no specific results or commentary are included in the excerpt.

FAQ

Frequently asked questions about AMRX stock

What is the AMRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Amneal Pharmaceuticals, Inc. have a median 12-month price target of $25, with estimates ranging from $20 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMRX stock a buy right now?

Of the 7 analysts covering Amneal Pharmaceuticals, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amneal Pharmaceuticals, Inc. 83 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMRX?

As at 17 Nov 2026, Amneal Pharmaceuticals, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will AMRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +14.3% from the last close, and Ticker Nerd's factor model ranks Amneal Pharmaceuticals, Inc. 83 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMRX stock forecast for 2030?

No analyst covering Amneal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $28 over the next 12 months.

How has AMRX stock performed over the past year?

Amneal Pharmaceuticals, Inc. returned +89.1% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amneal Pharmaceuticals, Inc. do?

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines.

What is the latest news on AMRX?

The most recent item we track (GlobeNewsWire, 17 Nov 2026): "Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®". Amneal announced that the European Commission granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.

Company

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines. Its current business centers on generics, injectables, biosimilars, and specialty branded pharmaceutical products, serving patients and healthcare providers across the United States and other international markets. The company operates through three main segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment spans a wide range of dosage forms and delivery systems, including oral solids, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, and transdermal therapies. The Specialty segment focuses on branded treatments for selected therapeutic areas, while AvKARE supplies pharmaceuticals, medical, and surgical products and services to governmental agencies. Headquartered in Bridgewater, New Jersey, Amneal Pharmaceuticals plays a significant role in expanding access to cost-effective and differentiated medicines within the global pharmaceutical market.

CEO Mr. Chirag K. Patel · 8,700 employees · United States · https://www.amneal.com